Colorectal Surgery for Stage II / III Primary Colorectal Cancer
Conditions
Brief summary
Observational case-control study in a retrospective cohort of patients with stage II or III colorectal cancer undergoing scheduled surgery.
Detailed description
Observational case-control study in a retrospective cohort of patients with stage II or III colorectal cancer undergoing scheduled surgery. Period January 2010-December 2014. Patients must have had at least 5 years of follow-up to define disease-free survival. From the cohort of patients previously studied in our center by immunohistochemistry, 31 we will select 10 cases with recurrence by random sampling and we will match 10 controls by leveling the propensity score (propensity score matching).
Interventions
OTHERAssess the difference in MOR-1 expression between healthy and tumor tissue
Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
Sponsors
Hospital Universitario La Fe
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients over 18 years of age. * Colorectal surgery scheduled between January 2010 - December 2014. * Stage II or III colon or rectum neoplasm (T3 / T4 N + M0).
Exclusion criteria
* Neoplasia of colon or rectum in Stage I or Stage IV. * Non-oncological colorectal surgery. * Urgent surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MOR-1 expression by polymerase chain reaction (RT-qPCR) in tumor tissue and adjacent healthy tissue. | Day 1 |
Secondary
| Measure | Time frame |
|---|---|
| Cancer-free survival 5 years after surgery (disease-free survival-DFS). | Day 1 |
| Degree of MOR-1 activation measured by immunohistochemistry through cAMP and PKA levels. | Day 1 |
| MOR-1 expression by immunohistochemistry in tumor tissue and adjacent healthy tissue. | Day 1 |
Other
| Measure | Time frame |
|---|---|
| Surgery time | Day 1 |
| Surgery date | Day 1 |
| Hospital discharge | Day 1 |
| Use of halogenated vs intravenous hypnotic agent | Day 1 |
| Type of surgery | Day 1 |
| ASA test | Day 1 |
| Concomitant Diseases | Day 1 |
| Surgery complications | Day 1 |
| Carcinoembryonic antigen | Day 1 |
| Cancer antigen | Day 1 |
| Neoadjuvant or adjuvant chemotherapy or radiation therapy | Day 1 |
Outcome results
None listed